Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.

@article{Katlama1996AtovaquoneAL,
  title={Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.},
  author={Christine Katlama and B Mouthon and Delphine Gourdon and Didier H Lapierre and Franck Rousseau},
  journal={AIDS},
  year={1996},
  volume={10 10},
  pages={1107-12}
}
OBJECTIVE To evaluate the efficacy and tolerance of atovaquone used as long-term maintenance therapy in patients with toxoplasmic encephalitis and intolerant of conventional anti-Toxoplasma therapies. DESIGN Uncontrolled open-label study of atovaquone given through an expanded access programme; statistical analysis was performed on an intent-to-treat basis. PATIENTS Sixty-five patients intolerant of conventional toxoplasmic encephalitis therapies-pyrimethamine, sulphadiazine or clindamycin… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Guidelines for the diagnosis and management of neurological complications of HIV infection

P. Portegiesa, L. Solodb, +7 authors P. G. E. Kennedyd
2004
View 4 Excerpts
Highly Influenced

Clinical case of the month: altered mental status and headache in a young man.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society • 2014

Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2013

Similar Papers

Loading similar papers…